• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    CAR T Funding Deal Could Be A Game Changer For Ligand Pharmaceuticals (LGND)

    Simply Wall St·09/30/2026 20:27:25
    Listen to the news
    • Ligand Pharmaceuticals has agreed to provide up to US$47 million in funding to AvenCell Therapeutics, with most of the capital linked to clinical milestones in AvenCell's CAR-T therapy programs and future royalty rights on its current and emerging pipeline.
    • This AvenCell deal deepens Ligand Pharmaceuticals' royalty focused model by adding milestone tied exposure to CAR-T therapies. It expands and diversifies its over 200 asset partnered portfolio without increasing internal R&D commitments.
    • We will look at how Ligand Pharmaceuticals' royalty focused investment narrative is influenced by the milestone linked AvenCell CAR-T funding.

    Scan royalty-focused healthcare platforms similar to Ligand Pharmaceuticals that could benefit from milestone-linked deals by reviewing our curated list of 17 high quality undiscovered gems.

    Ligand Pharmaceuticals Investment Narrative Recap

    For Ligand Pharmaceuticals, the core belief is that an asset light royalty model can keep generating high margin cash flows as more partnered drugs reach or move through the market. The AvenCell funding fits this idea by adding milestone linked CAR T exposure without increasing internal R&D, but it does not change the near term story.

    The key short term swing factor still sits with performance of existing royalty drivers like O2vir, Filspari, Qarziba and Zelsuvmi, along with partner execution and pricing trends. The biggest immediate risk remains concentration in those royalties in an environment where drug pricing pressure and regulatory shifts can quickly affect payoffs.

    The AvenCell agreement sits alongside earlier transactions such as the Sydnexis royalty deal and additional capital into Primrose Bio, which were already broadening Ligand Pharmaceuticals exposure across more partnered programs. Those earlier moves pointed to a consistent pattern. Management has been leaning into external partnerships to extend the royalty funnel rather than building a heavy in house pipeline.

    Relative to today’s catalysts, that earlier capital deployment matters. It means the current investment case rests on a growing spread of shots on goal while still accepting concentration in a handful of larger royalties. Execution risk now depends less on any single deal and more on whether this rolling series of partnerships, including AvenCell, can consistently translate into future cash flows.

    Ligand Pharmaceuticals' current analyst narrative points to US$481.1 million in revenue and US$273.9 million in earnings by 2029, based on a forecast 18.3% yearly revenue growth rate and a projected earnings increase of about US$76.7 million from US$197.2 million today.

    Uncover why Ligand Pharmaceuticals' fair value indicates a 10% potential upside to its current price, which could narrow quickly.

    NasdaqGM:LGND 1-Year Stock Price Chart
    NasdaqGM:LGND 1-Year Stock Price Chart

    Exploring Other Perspectives

    One alternate view on Ligand Pharmaceuticals leans heavily on operating leverage as the key catalyst. The most optimistic analysts were already assuming revenue could reach about US$537.9 million and earnings of roughly US$277.3 million by 2029, far above the baseline. You can treat the new AvenCell funding as a fresh test of those bolder expectations, and it is worth exploring how these pre-news forecasts might evolve from here.

    Explore another Ligand Pharmaceuticals fair value estimate, including one that suggests there could be as much as 38% upside from the current price!

    The Verdict Is Yours

    Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.

    Looking For More Investment Ideas Beyond Ligand Pharmaceuticals?

    If the AvenCell funding deal has sharpened your view on Ligand Pharmaceuticals, it can be useful to compare that thesis against other opportunities with different risk and return profiles. The Simply Wall St Screener helps you quickly scan groups of companies that match specific qualities so you can pressure test your thinking and broaden your watchlist.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.